AR105758A1 - COMPLEX PHARMACEUTICAL FORMULATION INCLUDING AMLODIPINA, LOSARTAN AND CLORTALIDONA - Google Patents

COMPLEX PHARMACEUTICAL FORMULATION INCLUDING AMLODIPINA, LOSARTAN AND CLORTALIDONA

Info

Publication number
AR105758A1
AR105758A1 ARP160100825A ARP160100825A AR105758A1 AR 105758 A1 AR105758 A1 AR 105758A1 AR P160100825 A ARP160100825 A AR P160100825A AR P160100825 A ARP160100825 A AR P160100825A AR 105758 A1 AR105758 A1 AR 105758A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
losartan
pharmaceutical formulation
mixture
salts
Prior art date
Application number
ARP160100825A
Other languages
Spanish (es)
Inventor
Soo Woo Jong
Hyun Park Jae
Yoon Youngsu
Roh Leedong
Taek Im Ho
Il Kim Yong
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR105758A1 publication Critical patent/AR105758A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una formulación farmacéutica compleja para prevenir o tratar las enfermedades cardiovasculares, donde la formulación comprende: una primera mezcla que incluye amlodipina o una de sus sales aceptables desde el punto de vista farmacéutico, clortalidona o una de sus sales aceptables desde el punto de vista farmacéutico, y un aditivo aceptable desde el punto de vista farmacéutico; y una segunda mezcla que incluye losartan o una de sus sales aceptables desde el punto de vista farmacéutico, y un aditivo aceptable desde el punto de vista farmacéutico, en donde la primera mezcla y la segunda mezcla están presentes en una forma separada físicamente una de la otra. Reivindicación 11: Un método para preparar una formulación farmacéutica compleja para prevenir o tratar las enfermedades cardiovasculares, donde el método comprende los pasos de: a) mezclar amlodipina o una de sus sales aceptables desde el punto de vista farmacéutico, clortalidona o una de sus sales aceptables desde el punto de vista farmacéutico, y un aditivo aceptable desde el punto de vista farmacéutico; y b) mezclar losartan o una de sus sales aceptables desde el punto de vista farmacéutico, y un aditivo aceptable desde el punto de vista farmacéutico.Claim 1: A complex pharmaceutical formulation for preventing or treating cardiovascular diseases, wherein the formulation comprises: a first mixture that includes amlodipine or one of its pharmaceutically acceptable salts, chlorthalidone or one of its salts acceptable from the point of view of pharmaceutical view, and a pharmaceutically acceptable additive; and a second mixture that includes losartan or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive, wherein the first mixture and the second mixture are present in a physically separate form one of the other. Claim 11: A method for preparing a complex pharmaceutical formulation for preventing or treating cardiovascular diseases, wherein the method comprises the steps of: a) mixing amlodipine or one of its pharmaceutically acceptable salts, chlorthalidone or one of its salts pharmaceutically acceptable, and a pharmaceutically acceptable additive; and b) mixing losartan or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive.

ARP160100825A 2015-03-31 2016-03-29 COMPLEX PHARMACEUTICAL FORMULATION INCLUDING AMLODIPINA, LOSARTAN AND CLORTALIDONA AR105758A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150045645A KR101914930B1 (en) 2015-03-31 2015-03-31 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone

Publications (1)

Publication Number Publication Date
AR105758A1 true AR105758A1 (en) 2017-11-08

Family

ID=57007292

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100825A AR105758A1 (en) 2015-03-31 2016-03-29 COMPLEX PHARMACEUTICAL FORMULATION INCLUDING AMLODIPINA, LOSARTAN AND CLORTALIDONA

Country Status (11)

Country Link
KR (1) KR101914930B1 (en)
CN (1) CN108289850B (en)
AR (1) AR105758A1 (en)
JO (1) JO3461B1 (en)
MX (1) MX2017012459A (en)
MY (1) MY190016A (en)
PH (1) PH12017501769A1 (en)
RU (1) RU2713883C2 (en)
TW (1) TWI714560B (en)
UY (1) UY36595A (en)
WO (1) WO2016159535A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101910902B1 (en) * 2016-11-03 2018-10-24 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
KR20180053044A (en) * 2016-11-11 2018-05-21 주식회사유한양행 A pharmaceutical composition in a monolithic matrix tablet form comprising chlorthalidone or its salt and amlodipine or its salt and a process for preparing the same
KR20200143914A (en) * 2019-06-17 2020-12-28 주식회사유한양행 A pharmaceutical composition in a multi-layered tablet form comprising amlodipine or its salt and chlorthalidone its salt
KR20210074428A (en) 2019-12-11 2021-06-22 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
KR20210152943A (en) 2020-06-09 2021-12-16 한미약품 주식회사 Pharmaceutical combination preparation for the prevention or treatment of cardiovascular diseases including amlodipine, losartan and chlorthalidone in a single layer tablet

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
EP0736021A4 (en) 1993-12-23 1997-04-02 Merck & Co Inc Polymorphs of losartan and the process for the preparation of form ii of losartan
KR100452491B1 (en) 2001-03-29 2004-10-12 한미약품 주식회사 A novel crystalline amlodipine camsylate and a preparing method thereof
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
JP2009513543A (en) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Chlorthalidone combination
US20070237815A1 (en) * 2006-04-06 2007-10-11 Lawrence Solomon Dosage forms and methods comprising amlodipine and chlorthalidone
KR101247583B1 (en) * 2006-12-08 2013-03-26 한미사이언스 주식회사 Pharmaceutical composition comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof
KR20090057538A (en) * 2007-12-03 2009-06-08 박사룡 A composition for treating hypertension comprising angiotensin ii antagonist, calsium andtagonist and diuretics
WO2009084040A1 (en) * 2007-12-28 2009-07-09 Rubicon Research Private Limited Once a day formulation of angiotensin receptor blockers
NZ594738A (en) 2009-01-23 2013-11-29 Hanmi Science Co Ltd Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
KR101907881B1 (en) * 2011-12-30 2018-12-11 한미약품 주식회사 Fixed dose combination formulation comprising losartan, amlodipine and hydrochlorothiazide
KR101392364B1 (en) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 Pharmaceutical composition comprising amlodipine and losartan having an improved stability

Also Published As

Publication number Publication date
RU2017134562A (en) 2019-04-04
JO3461B1 (en) 2020-07-05
RU2017134562A3 (en) 2019-08-15
MY190016A (en) 2022-03-22
TWI714560B (en) 2021-01-01
CN108289850A (en) 2018-07-17
PH12017501769B1 (en) 2018-03-19
CN108289850B (en) 2021-04-09
PH12017501769A1 (en) 2018-03-19
KR101914930B1 (en) 2018-11-05
KR20160117055A (en) 2016-10-10
MX2017012459A (en) 2018-01-30
UY36595A (en) 2016-10-31
RU2713883C2 (en) 2020-02-10
TW201639563A (en) 2016-11-16
WO2016159535A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
CL2017000902A1 (en) Ror-gamma inhibitor dihydropyrrolopyridines
DK3328843T3 (en) 1,3,4-OXADIAZOLESULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITORS AND THE PHARMACEUTICAL COMPOSITION
AR105758A1 (en) COMPLEX PHARMACEUTICAL FORMULATION INCLUDING AMLODIPINA, LOSARTAN AND CLORTALIDONA
CO2017004535A2 (en) Macrocyclic peptides that inhibit protein / protein interactions pd-1 / pd-l1 and cd80 / pdl1
CL2018001899A1 (en) Spiroheptane salicylamides and related compounds such as rho kinase inhibitors (rock)
EA201890126A1 (en) NEW BICYCLIC DERIVATIVES, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DK3330259T3 (en) 1,3,4-oxadiazolamide derivative compound as histone deacetylase-6 inhibitor and pharmaceutical composition containing this
DK3442973T3 (en) PREVIOUSLY UNKNOWN COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME
UY36660A (en) IRAK4 INHIBITORS COMBINATIONS
DK3328844T3 (en) 1,3,4-oxadiazole sulfamide derivatives as histone deacetylase-6 inhibitor and pharmaceutical composition comprising the same
EA201892838A1 (en) NEW PIPERIDINILIC DERIVATIVES, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY36151A (en) ? A PHARMACEUTICAL COMPOSITION THAT INCLUDES A 3-QUINASA DELTA PHOSFOINOSYTIDE INHIBITOR AND A CORTICOSTEROID ?.
GT201700023A (en) OPTIONALLY CONDENSED HYDERO-CYCLIC DERIVATIVES OF PIRIDIMINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOINMUNITY DISEASES
AR103895A1 (en) LACTAMAS AS ROCK INHIBITORS
CL2016001587A1 (en) Derivative based on 1,2-naphthoquinone and method of preparation thereof.
SV2017005412A (en) COMPOUNDS OF 1-RENT-6-OXO-1,6-DIHIDROPIRIDIN-3-ILO AND USES OF THE SAME
MA43402A (en) PHARMACEUTICAL COMPOSITION INCLUDING A POWERFUL URAT1 INHIBITOR
ECSP19051352A (en) JAK1 SELECTIVE INHIBITORS
DK3412660T3 (en) Sulfonamide derivative and pharmaceutical composition containing the same
AR101414A1 (en) PIRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS
CL2017000682A1 (en) Novel imidazopyridazine compounds and their use.
BR112017023225A2 (en) protein kinase inhibitor
DOP2016000297A (en) PHARMACEUTICAL COMPOSITIONS USEFUL TO TREAT INFECTIOUS DISEASES
CY1123408T1 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
DK3455216T3 (en) PYRIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AS AOC3 INHIBITORS